Work

The Theranostic Genome

Year: 2024

Type: article

Abstract: Theranostic drugs represent an emerging path to deliver on the promise of precision medicine. However, bottlenecks remain in characterizing theranostic targets, identifying theranostic lead compounds, and tailoring theranostic drugs. To overcome these bottlenecks, we present the Theranostic Genome, the part of the human genome whose expression can be utilized to combine therapeutic and diagnostic applications. Using a deep learning-based hybrid human-AI pipeline that cross-references PubMed, the Gene Expression Omnibus, DisGeNET, The Cancer Genome Atlas and the NIH Molecular Imaging and Contrast Agent Database, we bridge individual genes in human cancers with respective theranostic compounds. Cross-referencing the Theranostic Genome with RNAseq data from over 17’000 human tissues identifies theranostic targets and lead compounds for various human cancers, and allows tailoring targeted theranostics to relevant cancer subpopulations. We expect the Theranostic Genome to facilitate the development of new targeted theranostics to better diagnose, understand, treat, and monitor a variety of human cancers. Identifying theranostic compounds for precision medicine remains a difficult task. Here, the authors develop a deep learning-based hybrid human-AI pipeline to integrate and analyse multiple databases and multimodal datasets to establish the Theranostic Genome, which can be used to propose targeted theranostics therapies.

Source: Nature Communications

DOI: 10.1038/s41467-024-55291-x